Zavzpret (Zavegepant HCl) Patent Expiration, LOE Window & CMS Spending
Zavzpret (Zavegepant HCl) by Pfizer: FDA Orange Book core substance LOE 2034-06-26, 0 AB generics, $15.4M 2024 CMS Part D & Medicaid spend, and $1,100 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N216386 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2034-06-26 |
| Last Listed Patent or Exclusivity Date | 2034-06-26 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $15.4M |
| 2024 Medicare Part D Spend | $8.9M |
| 2024 Medicaid Spend | $6.5M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,100 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.